# reload+after+2024-01-23 14:29:51.106683
address1§One Glaukos Way
city§Aliso Viejo
state§CA
zip§92656
country§United States
phone§949 367 9600
fax§949 367 9984
website§https://www.glaukos.com
industry§Medical Devices
sector§Healthcare
longBusinessSummary§Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, an implantable device intended to reduce the intraocular pressure of the eye; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo California.
fullTimeEmployees§783
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Thomas William Burns', 'age': 62, 'title': 'Chairman & CEO', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 1500301, 'exercisedValue': 0, 'unexercisedValue': 30137536}, {'maxAge': 1, 'name': 'Mr. Joseph E. Gilliam', 'age': 47, 'title': 'President & COO', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 974585, 'exercisedValue': 0, 'unexercisedValue': 1159725}, {'maxAge': 1, 'name': 'Mr. Alex R. Thurman', 'age': 53, 'title': 'Senior VP & CFO', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 373400, 'exercisedValue': 0, 'unexercisedValue': 496858}, {'maxAge': 1, 'name': 'Mr. Chris M. Calcaterra', 'age': 63, 'title': 'Executive Vice President of Global Commercial Operations', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 198659, 'exercisedValue': 0, 'unexercisedValue': 1309919}, {'maxAge': 1, 'name': 'Dr. Tomas  Navratil Ph.D.', 'age': 46, 'title': 'Chief Development Officer', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 721510, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Mory  Gharib Ph.D.', 'title': 'Co-Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Christopher William Lewis', 'title': 'Vice President of Investor Relations & Corporate Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Diana A. Scherer', 'title': 'VP of Compliance & Deputy General Counsel', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Michele M. Allegretto', 'title': 'Senior Vice President of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Jane E. Rady', 'age': 75, 'title': 'Senior Vice President of Corporate Strategy & Business Development', 'yearBorn': 1948, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§1
boardRisk§7
compensationRisk§6
shareHolderRightsRisk§8
overallRisk§6
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.126
priceToSalesTrailing12Months§12.716995
currency§USD
dateShortInterest§1702598400
forwardEps§-1.96
pegRatio§-4.4
exchange§NYQ
quoteType§EQUITY
shortName§Glaukos Corporation
longName§Glaukos Corporation
firstTradeDateEpochUtc§1435239000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§31342110-c926-373b-8780-60d68478ea6f
gmtOffSetMilliseconds§-18000000
targetHighPrice§105.0
targetLowPrice§65.0
targetMeanPrice§87.33
targetMedianPrice§87.5
recommendationMean§1.9
recommendationKey§buy
numberOfAnalystOpinions§12
quickRatio§5.066
grossMargins§0.75655
ebitdaMargins§-0.2882
trailingPegRatio§None
